Gastric Cancer Market Trends 2025–2029: Forecasts for Key Growth Segments

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Gastric Cancer Market Over The Five-Year Period 2025–2029?

The gastric cancer market has shown significant growth in recent years. This market is anticipated to expand from $3.17 billion in 2024 to $3.64 billion in 2025, achieving a compound annual growth rate (CAGR) of 14.8%. The historical growth is linked to factors including an increasing elderly population, enhanced healthcare awareness, more frequent genetic mutations, the growing trend of unhealthy lifestyles, and improved cancer awareness.

The market for gastric cancer treatments is projected to experience substantial expansion over the coming years. This market is anticipated to reach a valuation of $6.37 billion by 2029, demonstrating a compound annual growth rate (CAGR) of 15.0%. Several factors are driving this anticipated growth, including a rise in obesity, expanding government initiatives, greater investments in healthcare, a heightened demand for oral medications, and an increasing availability of cancer treatment centers. Key developments expected during this period involve the adoption of combination chemotherapy, broadening product offerings, the use of robotic-assisted surgery, the development of targeted therapies, collaborative strategies, and more sophisticated diagnostic instruments.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20797&type=smp

Which Drivers Are Shaping The Gastric Cancer Industry’s Market Share?

The future expansion of the gastric cancer market is anticipated due to increasing obesity rates. Obesity is a medical condition characterized by excessive body fat accumulation, often defined by a body mass index (BMI) of 30 or higher, which can lead to various health problems. Obesity rates are rising due to factors such as poor diet, lack of physical activity, sedentary lifestyles, environmental influences, and genetic predispositions. Excess body fat, particularly visceral fat around the abdomen, is associated with a higher risk of developing gastric cancer as obesity triggers chronic inflammation and metabolic disturbances, both linked to cancer development, contributing to a rise in the demand for gastric cancer treatment. For instance, in March 2024, according to the World Health Organization, a Switzerland-based intergovernmental organization, approximately 1 in 8 people globally were living with obesity in 2022, with 2.5 billion adults aged 18 and older classified as overweight, including 890 million individuals living with obesity. Among adults, 43% were overweight, and 16% were living with obesity. Additionally, 37 million children under the age of 5 were overweight, while over 390 million children and adolescents aged 5–19 years were overweight, including 160 million living with obesity. Therefore, the rising obesity rates are driving the gastric cancer market.

What Are The Emerging Segments Gaining Attention In The Gastric Cancer Market?

The gastric cancermarket covered in this report is segmented –

1) By Type: Adenocarcinoma; Lymphoma; Gastrointestinal Stromal Tumor; Carcinoid Tumor; Other Types

2) By Diagnosis: Endoscopy; Biopsy; Imaging Tests; Exploratory Surgery; Other Diagnosis

3) By Treatment: Surgery; Radiation Therapy; Chemotherapy; Targeted Therapy; Palliative Care; Other Treatments

4) By Distribution Channel: Hospital Pharmacies; Specialty And Retail Pharmacies; Other Distribution Channels

Subsegments:

1) By Adenocarcinoma: Intestinal Type Adenocarcinoma; Diffuse Type Adenocarcinoma; Mixed Type Adenocarcinoma

2) By Lymphoma: Primary Gastric Lymphoma; Secondary Gastric Lymphoma

3) By Gastrointestinal Stromal Tumor (GIST): Primary GIST; Metastatic GIST

4) By Carcinoid Tumor: Gastric Carcinoid Type 1; Gastric Carcinoid Type 2; Gastric Carcinoid Type 3

5) By Other Types: Small Cell Carcinoma; Squamous Cell Carcinoma; Mixed Tumors

What Are The Latest Industry Trends Transforming The Gastric Cancer Market?

Leading companies in the gastric cancer market are concentrating on creating technologically advanced solutions, including companion diagnostic assays, to facilitate personalized treatment. A companion diagnostic assay is a test utilized to identify patients who are most likely to gain from a specific therapeutic treatment based on the presence of certain biomarkers. For instance, in October 2024, F. Hoffmann-La Roche Ltd., a Switzerland-based pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved its VENTANA CLDN18 (43-14A) RxDx Assay, which stands as the initial immunohistochemistry (IHC) companion diagnostic for assessing CLDN18 protein expression in gastric and gastroesophageal junction (GEJ) adenocarcinoma. This assay identifies patients eligible for targeted treatment with VYLOY (zolbetuximab) by measuring CLDN18 protein variants, primarily CLDN18.2. Employing the OptiView DAB IHC Detection Kit on the BenchMark ULTRA instrument, this test propels personalized healthcare forward, thereby broadening the treatment choices for gastric and GEJ adenocarcinoma.

Who Are The Core Companies Influencing The Gastric Cancer Market Landscape?

Major companies operating in the gastric cancer market are F. Hoffmann La Roche Ltd., Merck And Co. Inc., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Abbott Laboratories, Novartis AG, GlaxoSmithKline Plc, Eli Lilly and Company, Amgen Inc., Gilead Sciences Inc., Teva Pharmaceutical Industries Ltd., Boehringer Ingelheim, Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Ipsen Biopharmaceuticals Inc., Ono Pharmaceutical Co. Ltd., Samsung Biologics Co. Ltd., Celltrion Healthcare Co. Ltd., Biocon Limited, Hanmi Pharmaceuticals, Mylan N.V., Taiho Oncology Inc., Hikma Pharmaceuticals PLC, Taiho Pharmaceuticals Co. Ltd., AROG Pharmaceuticals Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/gastric-cancer-global-market-report

Which Region Currently Holds The Largest Share Of The Gastric Cancer Market?

North America was the largest region in the gastric cancer market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gastric cancer market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Gastric Cancer Market Report:

https://www.thebusinessresearchcompany.com/customise?id=20797&type=smp

Browse Through More Reports Similar to the Global Gastric Cancer Market 2025, By The Business Research Company

Gastric Cancer Drugs Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market-report

Gastric Cancer Drugs Global Market 2025

https://www.thebusinessresearchcompany.com/report/gastric-cancer-drugs-global-market

Gastric Volvulus Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/gastric-volvulus-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795